| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals, Inc. | 44.07B | 332.92 | 142.88 | 65.19% | 8.45% | 39.76% | 1.06% | 3.76 |
| SLXNWSilexion Therapeutics Ltd. | 63.6M | 0.03 | 0.00 | -132.54% | ||||
| EDITEditas Medicine, Inc. | 205.18M | 2.20 | -0.76 | -58.64% | -430.84% | -14.85% | 0.26 | |
| SGMOSangamo Therapeutics, Inc. | 92.01M | 0.43 | -0.88 | -67.2% | -331.28% | -17.44% | 1.34 | |
| CAMPCAMP4 Therapeutics Corporation | 210.49M | 4.49 | -1.69 | 86.29% | -14.04% | -133.54% | 0.14 | |
| SLNSilence Therapeutics plc | 256.95M | 5.44 | -1.71 | 70.47% | -252.16% | -84.61% | 0.00 | |
| PEPGPepGen Inc. | 202.89M | 6.22 | -2.18 | -57.35% | 0.16 | |||
| ARCTArcturus Therapeutics Holdings Inc. | 224.14M | 8.23 | -2.74 | -12.27% | -72.48% | -29.71% | 0.12 |
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 106K | 0 | 0 | 0 | 1.18M | 1.5M |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -106K | 0 | 0 | 0 | -1.18M | -1.5M |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | - | - | - | -27.11% |
| Operating Expenses | 1.25M | 1.88M | 27.11M | 68.3M | 83.58M | 96.23M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 628K | 853K | 8.11M | 14.22M | 16.64M | 21.26M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 620K | 1.12M | 23.8M | 54.08M | 68.13M | 76.48M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | -100K | -4.8M | 0 | -1.18M | -1.5M |
| Operating Income | -1.35M | -1.88M | -27.11M | -68.3M | -84.77M | -97.74M |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -38.63% | -1344.27% | -151.95% | -24.11% | -15.3% |
| EBITDA | -1.25M | -1.77M | -26.93M | -67.81M | -83.58M | -96.23M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | - | -41.59% | -1424.11% | -151.78% | -23.26% | -15.14% |
| D&A (Non-Cash Add-back) | 106K | 110K | 178K | 493K | 1.18M | 1.5M |
| EBIT | -1.35M | -1.88M | -27.11M | -68.3M | -84.77M | -90.6M |
| Net Interest Income | 6K | 8K | 0 | 2.79M | 6.4M | 7.14M |
| Interest Income | 6K | 8K | 0 | 2.79M | 6.4M | 7.14M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 8K | -12K | -172K | 2.9M | 6.21M | 7.14M |
| Pretax Income | -1.35M | -1.89M | -27.28M | -65.4M | -78.55M | -90.6M |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 3.71M | 73K | -617K |
| Effective Tax Rate % | 100% | 100% | 100% | 105.67% | 100.09% | 99.32% |
| Net Income | -1.35M | -1.89M | -27.28M | -69.1M | -78.63M | -89.98M |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | - | -40.34% | -1344.2% | -153.3% | -13.78% | -14.44% |
| Net Income (Continuing) | -1.35M | -1.89M | -27.28M | -69.1M | -78.63M | -89.98M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.06 | -0.18 | -1.22 | -4.42 | -3.30 | -2.85 |
| EPS Growth % | - | -199.5% | -577.78% | -262.3% | 25.34% | 13.64% |
| EPS (Basic) | -0.06 | -0.53 | -1.22 | -4.42 | -3.30 | -2.85 |
| Diluted Shares Outstanding | 22.39M | 22.39M | 22.39M | 15.64M | 23.8M | 31.58M |
| Basic Shares Outstanding | 22.39M | 7.72M | 22.39M | 15.64M | 23.8M | 31.58M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 3.77M | 10.32M | 139.99M | 186.08M | 112.68M | 123.76M |
| Cash & Short-Term Investments | 3.49M | 9.78M | 132.9M | 181.75M | 110.41M | 120.19M |
| Cash Only | 3.49M | 9.78M | 132.9M | 181.75M | 80.77M | 49.42M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 29.63M | 70.77M |
| Accounts Receivable | 230K | 407K | 4.74M | 58K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 4.27M | 2.27M | 3.57M |
| Total Non-Current Assets | 419K | 323K | 3.65M | 31.36M | 30.37M | 27.12M |
| Property, Plant & Equipment | 419K | 323K | 636K | 29.88M | 28.38M | 25.15M |
| Fixed Asset Turnover | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 1.47M | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 1.55M | 1.47M | 1.99M | 1.97M |
| Total Assets | 4.19M | 10.64M | 143.64M | 217.44M | 143.05M | 150.88M |
| Asset Turnover | - | - | - | - | - | - |
| Asset Growth % | - | 153.8% | 1249.76% | 51.38% | -34.21% | 5.47% |
| Total Current Liabilities | 326K | 838K | 10.32M | 18.83M | 17.53M | 16.7M |
| Accounts Payable | 141K | 721K | 3.24M | 1.36M | 1M | 1.75M |
| Days Payables Outstanding | 485.52 | - | - | - | 309.82 | 424.9 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 28K | 1.21M | 2.44M | 2.37M | 3.62M |
| Current Ratio | 11.58x | 12.31x | 13.56x | 9.88x | 6.43x | 7.41x |
| Quick Ratio | 11.58x | 12.31x | 13.56x | 9.88x | 6.43x | 7.41x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 30K | 226K | 18.98M | 17.1M | 15.57M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 18.98M | 17.1M | 15.57M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 30K | 226K | 0 | 0 | 0 |
| Total Liabilities | 326K | 868K | 10.55M | 37.81M | 34.63M | 32.26M |
| Total Debt | 0 | 0 | 0 | 24.53M | 20.1M | 18.66M |
| Net Debt | -3.49M | -9.78M | -132.9M | -157.22M | -60.67M | -30.76M |
| Debt / Equity | - | - | - | 0.14x | 0.19x | 0.16x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - |
| Total Equity | 3.87M | 9.77M | 133.09M | 179.63M | 108.42M | 118.62M |
| Equity Growth % | - | 152.75% | 1261.71% | 34.97% | -39.64% | 9.41% |
| Book Value per Share | 0.17 | 0.44 | 5.94 | 11.49 | 4.56 | 3.76 |
| Total Shareholders' Equity | 3.87M | 9.77M | 133.09M | 179.63M | 108.42M | 118.62M |
| Common Stock | 0 | 0 | 0 | 2K | 2K | 3K |
| Retained Earnings | -2.39M | -6.47M | -33.75M | -102.86M | -181.48M | -271.46M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -8K | -8K | 17K | -81K | 34K | 23K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -885K | -1.65M | -22.6M | -59.27M | -69M | -82.37M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | - | -86.67% | -1267.98% | -162.25% | -16.42% | -19.38% |
| Net Income | -1.35M | -1.89M | -27.28M | -69.1M | -78.63M | -89.98M |
| Depreciation & Amortization | 106K | 110K | 178K | 493K | 850K | 5.25M |
| Stock-Based Compensation | 0 | 119K | 1.53M | 4.76M | 7.05M | 11.46M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 59K | 0 | 196K | 76K | -220K | -3.85M |
| Working Capital Changes | 296K | 8K | 2.77M | 4.51M | 1.95M | -5.25M |
| Change in Receivables | -112K | -170K | -4.34M | 4.18M | 26K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 59K | 331K | 2.51M | -1.41M | -369K | 722K |
| Cash from Investing | -29K | -8K | -500K | -3.75M | -32M | -37.67M |
| Capital Expenditures | -29K | -8K | -500K | -3.75M | -2.6M | -497K |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 2.79M | 7.95M | 147.66M | 112.19M | -189K | 88.75M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 0 | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -3K | -1.39M | -2.07M | -189K | 1.97M |
| Net Change in Cash | 1.88M | 6.29M | 124.59M | 48.86M | -100.9M | -31.35M |
| Free Cash Flow | -914K | -1.66M | -23.1M | -63.02M | -71.6M | -82.87M |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | - | -81.62% | -1291.51% | -172.83% | -13.61% | -15.75% |
| FCF per Share | -0.04 | -0.07 | -1.03 | -4.03 | -3.01 | -2.62 |
| FCF Conversion (FCF/Net Income) | 0.66x | 0.87x | 0.83x | 0.86x | 0.88x | 0.92x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 2.7M | 71K |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -34.81% | -27.7% | -38.19% | -44.19% | -54.59% | -79.26% |
| Return on Invested Capital (ROIC) | - | -756.85% | -20853.08% | -453.08% | -181.22% | -108.11% |
| Debt / Equity | - | - | - | 0.14x | 0.19x | 0.16x |
| FCF Conversion | 0.66x | 0.87x | 0.83x | 0.86x | 0.88x | 0.92x |
Explore detailed financial history, valuation models, and returns analysis
DCF models, peer multiples & analyst estimates
Historical returns with dividends reinvested
Yield, growth, payout safety & DRIP calculator
EPS trends, net income & profitability analysis
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of valuation, profitability & efficiency metrics